Skip to main content

Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.

Publication ,  Journal Article
Uhl, GR; Walther, D; Musci, R; Fisher, C; Anthony, JC; Storr, CL; Behm, FM; Eaton, WW; Ialongo, N; Rose, JE
Published in: Mol Psychiatry
January 2014

Genotype scores that predict relevant clinical outcomes may detect other disease features and help direct prevention efforts. We report data that validate a previously established v1.0 smoking cessation quit success genotype score and describe striking differences in the score in individuals who display differing developmental trajectories of use of common addictive substances. In a cessation study, v1.0 genotype scores predicted ability to quit with P=0.00056 and area under receiver-operating characteristic curve 0.66. About 43% vs 13% quit in the upper vs lower genotype score terciles. Latent class growth analyses of a developmentally assessed sample identified three latent classes based on substance use. Higher v1.0 scores were associated with (a) higher probabilities of participant membership in a latent class that displayed low use of common addictive substances during adolescence (P=0.0004) and (b) lower probabilities of membership in a class that reported escalating use (P=0.001). These results indicate that: (a) we have identified genetic predictors of smoking cessation success, (b) genetic influences on quit success overlap with those that influence the rate at which addictive substance use is taken up during adolescence and (c) individuals at genetic risk for both escalating use of addictive substances and poor abilities to quit may provide especially urgent focus for prevention efforts.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Mol Psychiatry

DOI

EISSN

1476-5578

Publication Date

January 2014

Volume

19

Issue

1

Start / End Page

50 / 54

Location

England

Related Subject Headings

  • Young Adult
  • Varenicline
  • Tobacco Use Disorder
  • Tobacco Use Cessation Devices
  • Substance-Related Disorders
  • Smoking Cessation
  • Risk Factors
  • Reproducibility of Results
  • Quinoxalines
  • Psychiatry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Uhl, G. R., Walther, D., Musci, R., Fisher, C., Anthony, J. C., Storr, C. L., … Rose, J. E. (2014). Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Mol Psychiatry, 19(1), 50–54. https://doi.org/10.1038/mp.2012.155
Uhl, G. R., D. Walther, R. Musci, C. Fisher, J. C. Anthony, C. L. Storr, F. M. Behm, W. W. Eaton, N. Ialongo, and J. E. Rose. “Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.Mol Psychiatry 19, no. 1 (January 2014): 50–54. https://doi.org/10.1038/mp.2012.155.
Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Mol Psychiatry. 2014 Jan;19(1):50–4.
Uhl, G. R., et al. “Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.Mol Psychiatry, vol. 19, no. 1, Jan. 2014, pp. 50–54. Pubmed, doi:10.1038/mp.2012.155.
Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, Behm FM, Eaton WW, Ialongo N, Rose JE. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. Mol Psychiatry. 2014 Jan;19(1):50–54.

Published In

Mol Psychiatry

DOI

EISSN

1476-5578

Publication Date

January 2014

Volume

19

Issue

1

Start / End Page

50 / 54

Location

England

Related Subject Headings

  • Young Adult
  • Varenicline
  • Tobacco Use Disorder
  • Tobacco Use Cessation Devices
  • Substance-Related Disorders
  • Smoking Cessation
  • Risk Factors
  • Reproducibility of Results
  • Quinoxalines
  • Psychiatry